Among patients who had at least a one-point reduction in pain intensity during three weeks of treatment with tapentadol ER, those who continued on a 100 to 250 mg twice-daily dose for an additional 12 weeks experienced significantly better pain control compared to those who switched to a placebo, the study found.

Adverse effects among these patients included nausea (21.1 percent) and vomiting (12.7 percent).

Related Articles on Pain Management:

Study Targets Effective Adolescent Migraine Relief
Athletes' Higher Pain Tolerance May Pave Way for Pain Management Research
New Treatment Uses IV Injections for Severe Migraines